ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers
HOXB13 is frequently co-gained with ERBB2 at both low-copy number level or as complex high-level amplification with relative BRCA1 loss. ERBB2/HOXB13 amplified, BRCA1-lost tumors are strongly enriched in breast cancer, and patients with such breast tumors experience a shortened PFS.
Authors
- A. John Iafrate
- Dennis C. Sgroi (ORCID: https://orcid.org/0000-0003-4052-6659)
- Irene Mitsiades (ORCID: https://orcid.org/0000-0002-9734-6803)
- D. Gulhan (ORCID: https://orcid.org/0000-0001-5419-0549)
- Esther Rheinbay (ORCID: https://orcid.org/0000-0002-5566-6729)
- Maristela L. Onozato (ORCID: https://orcid.org/0000-0003-2619-1848)
- Daniel Hicks
Institutions
- Broad Institute (US)
- Harvard University (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Center for Cancer Research (US)
- Vertex Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s13058-024-01943-1
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Breast Cancer Research Foundation